Treatment results of lymphoblastic lymphomas from progenitor cells according to ALL IC-BFM 2002/2009 protocols: monocenter clinical trial
https://doi.org/10.35754/0234-5730-2024-69-2-140-152
Abstract
Introduction. The acute lymphoblastic leukemia (ALL) therapy programs developed by the BFM group (Berlin-Frankfurt-Munster) are used to treat lymphoblastic lymphomas from precursor cells (LBL) and are the most effective treatment methods in the world.
Aim. To assess the treatment results of LBL in children according to the ALL IC-BFM 2002/2009 protocols in a clinical trial of a single center.
Materials and methods. From 2002 to 2022 a retrospective and prospective study included 70 patients aged 2 to 17 years with newly diagnosed LBL, with a median age of 9.4 years. There were 1.5 times more male patients than female (43:27). LBL from T-cells progenitor (T-LBL) was diagnosed in 61 patients (87 %), and LBL from B-cells progenitor (B-LBL) — in 9 (13 %). 59 (84.3 %) patients were included in the intermediate risk (IR) group and 11 (15.7 %) patients — in high-risk (HR) group. There were no patients in the study cohort who met the criteria of the standard risk group (SR).
Results. The 10-year OS in the group of patients treated according to the ALL IC-BFM 2002/2009 protocols was 95.4 ± 2.6 %; the 10-year RFS — 91.9 ± 4.9 %; the 10-year EFS — 86.7 ± 5.6 %. When analyzing survival rates depending on the prognostic risk group, the 10-year OS for patients of the intermediate risk group was 96.6 ± 2.6 %, and for patients of the high-risk group — 90.9 ± 8.7 %.
Conclusions. The obtained results confirm the high effectiveness of the ALL IC-BFM 2002/2009 protocols in the treatment of LBL.
About the Authors
T. Yu. Pavlova
Pediatric Oncology and Hematology Research Institute of N.N. Blok hin National Medical Research Center of Oncology, Ministry of Health of the Russia
Russian Federation
Russian Federation
Tatyana Y. Pavlova, Hematologist of the Department of Pediatric Oncology and Hematology (Hemoblastosis Chemotherapy) No. 1
24 Kashirskoye Shosse, Moscow 115522
T. T. Valiev
Pediatric Oncology and Hematology Research Institute of N.N. Blok hin National Medical Research Center of Oncology, Ministry of Health of the Russia
Russian Federation
Russian Federation
Timur T. Valiev, Dr. Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) №1
24 Kashirskoye Shosse, Moscow 115522
S. R. Varfolomeeva
Pediatric Oncology and Hematology Research Institute of N.N. Blok hin National Medical Research Center of Oncology, Ministry of Health of the Russia
Russian Federation
Russian Federation
Svetlana R. Varfolomeeva, Dr. Sci. (Med.), Professor, Director
24 Kashirskoye Shosse, Moscow 115522
References
1. Felix H., Ougier J., Pirollet H., et al. Leucosarcomatose de Sternberg. (a propos de 7 observations). Lyon Med. 1964; 211: 1047–97.
2. Barcos M.P., Lukes R.J. Malignant lymphoma of convoluted lymphocytes: A new entity of possible T-cell type. In: Conflicts in Childhood Cancer. Sinks L.F, Godden J.E. (eds.). New York: Alan R. Liss 1975. 147 p.
3. Burkhardt B., Zimmermann M., Oschlies I., et al. BFM Group. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005; 131(1): 39–49. DOI: 10.1111/j.1365-2141.2005.05735.x.
4. Oschlies I., Burkhardt B., Chassagne-Clement С., et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011; 35(6): 836–44. DOI: 10.1097/PAS.0b013e318213e90e.
5. Termuhlen A.M., Smith L.M., Perkins S.L., et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol. 2013; 162(6): 792–801. DOI: 10.1111/bjh.12460.
6. Landmann E., Burkhardt B., Zimmermann M., et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017; 102(12): 2086–96. DOI: 10.3324/haematol.2015.139162.
7. Schmidt E., Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013; 30(6): 484–508. DOI: 10.3109/08880018.2013.789574.
8. Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720–48. DOI: 10.1038/s41375-023-01962-5.
9. Rosolen A., Perkins S.L., Pinkerton C.R., et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015; 33(18): 2112–8. DOI: 10.1200/JCO.2014.59.7203.
10. Вurkhardt B., Bruch J., Zimmermann M., et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006; 20(8): 1422–9. DOI: 10.1038/sj.leu.2404275.
11. Basso K., Mussolin L., Lettieri A., et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011; 50(12): 1063–75. DOI: 10.1002/gcc.20924.
12. Feng H., Stachura D.L., White R.M., et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 2010; 18(4): 353–66. DOI: 10.1016/j.ccr.2010.09.009.
13. Meyer J.A., Zhou D., Mason C.C., et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer. 2017; 64(7). DOI: 10.1002/pbc.26363.
14. Pui C., Roberts K., Yang J., et al. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2017; 17(8): 464–70. DOI: 10.1016/j.clml.2017.03.299.
15. Knez V., Bao L., Carstens B., et al. Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood. Leuk Lymphoma. 2020; 61(9): 2129–35. DOI: 10.1080/10428194.2020.1761970.
16. Hoelzer D., Gokbuget N., Digel W., et al. Outcome of adult patients with Tlymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002; 99(12): 4379–85. DOI: 10.1182/blood-2002-01-0110.
17. Reiter A., Schrappe M., Ludwig W.D, et al. Intensive ALL type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000; 95(2): 416–21.
18. Patte C., Kalifa C., Flamant F., et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-Bcell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992; 20(2): 105–13. DOI: 10.1002/mpo.2950200204.
19. Dahl G.V., Rivera G., Pui C.H., et al. A novel treatment of childhood lymphoblastic non-Hodgkin’s lymphoma: early and intermittent use of teniposide plus cytarabine. Blood. 1985; 66(5): 1110–4.
20. Weinstein H.J, Cassady J.R, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol. 1983; 1(9): 537–41.
21. Wollner N., Burchenal J.H., Lieberman P.H., et al. Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976; 37(1): 123–34. DOI: 10.1002/1097-0142(197601)37:1<123::aidcncr2820370119>3.0.co;2-7.
22. Cortelazzo S., Ferreri A., Hoelzer D., et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2017; 113: 304–17. DOI: 10.1016/j.critrevonc.2017.03.020.
23. Wollner N., Exelby R., Lieberman P.H. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979; 44(6): 1990–9. DOI: 10.1002/1097-0142(197912)44:6<1990::aidcncr2820440605>3.0.co;2-9.
24. Valiev T.T., Shervashidze M.A., Osipova I.V., et al. ALL-IC BFM Protocol 2002: results of treatment of acute lymphoblastic leukemia in children in a multicenter clinical trial. Klinicheskaya Onkogematologiya. 2022; 15(2): 119–29 (In Russian). DOI: 10.21320/2500-2139-2022-15-2-119-129.
25. Burkhardt B., Hermiston M.L. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019; 185(6): 1158–70. DOI: 10.1111/bjh.15793.
26. Campbell M., Kiss C., Zimmermann M., et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Munster 2009 Trial. J Clin Oncol. 2023; 41(19): 3499–511. DOI: 10.1200/JCO.22.01760.
27. Temple W.C., Mueller S., Hermiston M.L., et al. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best Pract Res Clin Haematol. 2023; 36(1): 101449. DOI: 10.1016/j.beha.2023.101449.
28. Aleshina O.A., Galtseva I.V., Kotova E.S., et al. Treatment outcomes for acute T-lymphoblastic leukemias/lymphomas: data from the ALL-2016 multicenter prospective randomized trial. Onkogematologiya. 2023; 18(1): 20–30 (In Russian). DOI: 10.17650/1818-8346-2023-18-1-20-30.
29. Patte C., Kalifa C., Flamant F., et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-Bcell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992; 20(2): 105–13. DOI: 10.1002/mpo.2950200204.
30. Amylon M.D., Shuster J., Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999 Mar; 13(3): 335–42. DOI: 10.1038/sj.leu.2401310.
31. Gao Y.J., Pan C., Tang J.Y., et al. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001–2010. Pediatr Blood Cancer. 2014 Apr; 61(4): 659–63. DOI: 10.1002/pbc.24848.
32. Sandlund J.T., Pui C.H., Zhou Y., et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009; 23(6): 1127–30. DOI: 10.1038/leu.2008.400.
33. Uyttebroeck A., Suciu S., Plat G., et al. Dexamethasone (DEX) versus prednisone (PRED) in T-cell non Hodgkin lymphoma (T-NHL): results of the randomized phase III trial 58951 of the EORTC Children Leukemia Group. Br J Haematol. 2012; 159(1): 37.
34. Hayashi R.J., Winter S.S., Dunsmore K.P., et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434. J Clin Oncol. 2020; 38(26): 3062–70. DOI: 10.1200/JCO.20.00531.
35. Teachey D.T., Devidas M., Wood B.L., et al. Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed TCell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022; 40(19): 2106–18. DOI: 10.1200/JCO.21.02678.
36. Polyatskin I.L., Artem’eva A.S., Krivolapov Yu.A. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4 th edition): lymphoid tumors. Archiv Patologii. 2019; 81(3): 59–65 (In Russian). DOI: 10.17116/patol20198103159.
37. Jaffe E. S., Harris N. L., Stein H., et al. WHO Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001. 352 p
38. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937–51. DOI: 10.1182/blood-2009-03-209262.
Review
For citations:
Pavlova T.Yu., Valiev T.T., Varfolomeeva S.R. Treatment results of lymphoblastic lymphomas from progenitor cells according to ALL IC-BFM 2002/2009 protocols: monocenter clinical trial. Russian journal of hematology and transfusiology. 2024;69(2):140-152. (In Russ.) https://doi.org/10.35754/0234-5730-2024-69-2-140-152
Views:
398
Email this article 
